期刊文献+

GCP方案治疗复发或难治性非霍奇金淋巴瘤的临床观察 被引量:7

下载PDF
导出
摘要 非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL)是1种常见的恶性肿瘤,目前常用的治疗方案为以CHOP方案为主的综合治疗,治愈率为50%~60%,但仍有部分患者治疗后不能缓解或缓解后很快复发。目前国内外尚无标准的治疗方案,许多学者已做了较多探索,亦取得了一定成果。我院在2008年6月至2010年2月以GCP方案治疗25例复发或难治性NHL,取得了较好的效果,报告如下。
机构地区 解放军第
出处 《实用癌症杂志》 2011年第2期202-203,共2页 The Practical Journal of Cancer
  • 相关文献

参考文献6

  • 1张之南,沈悌.血液病诊断及疗效效标准[M].第2版.北京:科学出版社,1998:349-360.
  • 2卢学春,于力.难治性淋巴瘤的药物治疗进展[J].解放军医学杂志,2008,33(10):1272-1274. 被引量:6
  • 3Moskowitz CH, Zelenetz AD, Kewalramani T, et al. Cell of origin, germinal center versus nongerminal center, determined by immuno2histochemistry on tissue microarray, does not correlale with outcome inpatients with relapsed and refractory DLBCL[J]. lood, 2005,106 (10) :3383.
  • 4Waters J, Chau I, Norman AR, et al. Gemeitabine ( GEM ) , cisplatin (P) and methyprednisolone : A salvage regimen in relapsed Hodgkin' s disease and non-Hodgkin' s lymphoma(J]. J Clin 0ncol,2004 ASCO Annual Meeting Proceedings ( Post Meeting Edition ), 2004,22 ( 14S ) : 6589.
  • 5马树东,盛信秀,罗荣城,李爱民.盐酸吉西他滨治疗复发性或难治性非霍奇金淋巴瘤[J].中华肿瘤杂志,2002,24(6):619-621. 被引量:36
  • 6万莉娟,鄢冰琪,陈建祥.吉西他滨等联合治疗复发性非霍奇金淋巴瘤[J].江西医学院学报,2006,46(2):152-152. 被引量:10

二级参考文献25

  • 1易克,许小平.吉西他滨治疗恶性血液病的研究进展[J].国外医学(输血及血液学分册),2005,28(4):364-367. 被引量:5
  • 2沈志祥,周励.复发难治性淋巴瘤的治疗进展[J].临床内科杂志,2005,22(9):580-582. 被引量:18
  • 3MARTELLI M,de SANCTIS V,AVVISSATI G,et al.Current Guidelines for the Management of Aggressive Non-Hodgkin's Lymphoma[J].Drugs,1997,53(6):957-972.
  • 4KIMBY E,BRANDT L,NYGREN P,et al.A Systematic Overview of Chemotherapy Effects in Aggressive Non-Hodgkin's Lymphoma[J].Acta Onco1,2001,40(2-3):198-2l2.
  • 5VELASQUEZ W S,MCLAUGHLIN P,TUCKER S,et al.ESHAP-an Effective Chemotherapy Regimen in Refractory and Relapsing Lymphoma:a-Year Follow-up Study[J].J Clin Oncol,1994,12:l169-l176.
  • 6Moskowitz CH, Zelenetz AD, Kewalramani T, et al. Cell of origin, germinal center versus nongerminal center, determined by immuno histochemistry on tissue mieroarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood, 2005, 106 (10) : 3383
  • 7Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reducedintensity allogeneie progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood,2002,100(13) :4310
  • 8Lai R, Bartlett NL, Mackey JR, et al. High expression of nucleoside transporter protein bENT1 in Reed-Steinberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelhine and liposomal doxorubicin - a CALGB 59804 correlative study. Leuk Lymphoma,2008,49(6) : 1202
  • 9Philip T, GuglielmiC, HagenbeekA, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 1995,333(23) : 1540
  • 10Philip T, Amaitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade nonHodgkins lyrnphoma. N Engl J Med, 1987,316(24) :1493

共引文献44

同被引文献53

引证文献7

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部